Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

ECARX (ECX) Q4 2025 Earnings Call Transcript

View original at finance.yahoo.com
ECARX (ECX) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. Date Thursday, February 12, 2026 at 8 a.m. ET Call participants Chief Executive Officer — Ziyu Shen Chief Operating Officer — Peter W…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Overall automotive market in Q1 impacted by policy changes and end user demand shrinking, with some reports showing estimation of 20% decrease or worse in auto wholesale Q1 YoY

    80% confidence

  • 2025 represents a strategic inflection point in ECARX's evolution, successfully navigating macroeconomic headwinds to deliver second consecutive quarter of positive operating income and EBITDA

    80% confidence

  • Gross margin outlook for 2026 is range of 15-18%

    80% confidence

  • ECARX targets to generate 50% of total revenue from overseas markets by 2030

    80% confidence

  • ECARX proudly serves 18 OEMs across 28 brands worldwide

    80% confidence

  • ECARX is transforming vehicles into seamlessly integrated information, communication, and transportation devices with vision of becoming a leading AI technology provider in the automotive industry

    80% confidence

  • Auto demand has been impacted by weakening of government-supported policies in Q1 2026

    80% confidence

  • Partnership with Volkswagen Group continues to progress smoothly with sample development and delivery consistently meeting all targets and exceeding expectations

    80% confidence

  • ECARX is working to obtain relevant regulatory certifications in the US to engage with US automakers

    80% confidence

  • ECARX expects total revenue for full year 2026 in range of $1.0-1.1 billion, representing 20-30% YoY increase, with commitment to maintain positive operating income throughout 2026

    80% confidence

  • ECARX targets to meaningfully increase share of total revenue from international markets by end of decade

    80% confidence

  • Q1 2026 represents a softer period for automotive consumption following Q4 peak, with seasonal fluctuations typical of the industry

    80% confidence

  • Antora platform has obtained key safety and privacy certifications for European market entry

    80% confidence

  • ECARX has broad level of significant opportunities emerging from engagement with European partners, with hope that pipeline will pay well with additional wins that will contribute to revenue in future

    80% confidence

  • ECARX target for 2026 is to continue to generate meaningful annual revenue growth and maintain positive operating income throughout 2026

    80% confidence

  • Q4 2025 was a critical inflection point marking the start of ECARX's next phase of sustainable profitable growth

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com
ECARX (ECX) Q4 2025 Earnings Call Transcript — Source | Via News | Via News